Construction of an Expression Vector for Production and Purification of Human Somatostatin in Escherichia coli

被引:8
作者
Maicas, Sergi [1 ]
Moukadiri, Ismail [2 ]
Nieto, Almudena [1 ]
Valentin, Eulogio [1 ]
机构
[1] Univ Valencia, Dept Microbiol & Ecol, E-46100 Burjassot, Spain
[2] Ctr Invest Principe Felipe, Genet Mol Lab, Valencia 46013, Spain
关键词
Escherichia coli; Expression; FPLC; HPLC; Human somatostatin; Ion exchange purification; FERMENTATION PROCESSES; PROTEINS; PROMOTERS; PEPTIDES; DRUGS; GENE;
D O I
10.1007/s12033-013-9667-3
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Somatostatin/growth hormone-inhibiting hormone is the peptide that inhibits secretion of somatotropin/growth hormone. Solid-phase synthesis methods are being currently used to produce somatostatin. Recombinant peptide synthesis is widely described for the production of small proteins and peptides; however, the production at industrial scale of peptides for biopharmaceutical applications is limited for economic reasons. Here, we propose the use of a new pGB-SMT plasmid to produce Somatostatin, as a C-terminal fusion protein with a Kluyveromyces lactis beta-galactosidase fragment. To facilitate removal of that fragment by CNBr cleavage, a methionine residue was introduced at the N-terminal of the hormone peptide. The use of this construction enables an IPTG-free expression system. The suitability of this procedure has been assessed in a 15 l scale-up experiment yielding almost 300 mg, with purity > 99 % and it is being implemented for commercial scale. The plasmid pGB-SMT here described is an alternative option for a cheap and high expression of other short peptide hormones.
引用
收藏
页码:150 / 158
页数:9
相关论文
共 32 条
  • [1] Developments in peptide and amide synthesis
    Albericio, F
    [J]. CURRENT OPINION IN CHEMICAL BIOLOGY, 2004, 8 (03) : 211 - 221
  • [2] [Anonymous], [No title captured]
  • [3] [Anonymous], 2012, Molecular Cloning: A Laboratory Manual
  • [4] From production of peptides in milligram amounts for research to multi-tons quantities for drugs of the future
    Bruckdorfer, T
    Marder, O
    Albericio, F
    [J]. CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2004, 5 (01) : 29 - 43
  • [5] Secretory and extracellular production of recombinant proteins using Escherichia coli
    Choi, JH
    Lee, SY
    [J]. APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, 2004, 64 (05) : 625 - 635
  • [6] Cserjan-Puschmann M, 2002, BIOPHARM-APPL T BIO, V15, P26
  • [7] Metabolic approaches for the optimisation of recombinant fermentation processes
    Cserjan-Puschmann, M
    Kramer, W
    Duerrschmid, E
    Striedner, G
    Bayer, K
    [J]. APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, 1999, 53 (01) : 43 - 50
  • [8] His-Tagged Protein Purification by Metal-Chelate Affinity Extraction with Nickel-Chelate Reverse Micelles
    Dong, Xiao-Yan
    Feng, Xu-Dong
    Sun, Yan
    [J]. BIOTECHNOLOGY PROGRESS, 2010, 26 (04) : 1088 - 1094
  • [9] Grindley J., 2000, UNDERSTANDING BIOPHA
  • [10] Grosjean H., 1982, GENE, V18, P99